Nordion is a global health science company that provides sterilization and medical isotope products. It has approximately 400 employees and supplies over 500 customers in more than 40 countries. In fiscal year 2013, Nordion reported revenues of $232.8 million, with sterilization technologies and medical isotopes being its two business segments. Nordion is focused on maintaining its leadership in sterilization and optimizing its medical isotopes business to secure long-term supply and customer relationships.
Nordion is a global health science company that provides market-leading products used for the prevention, diagnosis and treatment of disease. We are a leading provider of medical isotopes, targeted therapies and sterilization technologies that benefit the lives of millions of people in more than 60 countries around the world.
AHMC’s successful track record includes collaboration in more than 50 hospitals and projects spanning 24 countries around the world. AHMC’s hospital network consists of 32 hospital and healthcare centers, among them 13 operational facilities consisting of nearly 3,000 beds, 2,200 physicians and 5,500 employees which it has either invested in or currently manages.
ClinActis Pte Ltd is a full service CRO providing clinical trial services to the pharmaceutical, medical device, medical nutrition and biotech companies in Asia Pacific. Established in 2009, ClinActis Pte Ltd is headquartered in Singapore.
ClinActis Experience
• 45 years experience in clinical research in pharmaceutical and biotechnology companies as well as CROs
• 27 years experience in Asia Pacific, including Australia/New Zealand, China, Malaysia, Hong Kong, India, Indonesia, The Philippines, Singapore, South Korea, Taiwan, Thailand and Japan
• Extensive knowledge of regulatory frameworks, best KOLs and sites across the region
• Vast therapeutic experience including Cardiovascular, CNS, Endocrinology, Infectious diseases, Oncology, and Respiratory
Market Analysis of Clinical Research in Asia PacificClinActis Pte Ltd
ClinActis Pte Ltd is a full service CRO providing clinical trial services to the pharmaceutical, medical device, medical nutrition and biotech companies in Asia Pacific. Established in 2009, ClinActis Pte Ltd is headquartered in Singapore.
ClinActis Experience
• 33 years experience in clinical research in pharmaceutical and biotechnology companies as well as CROs
• 27 years experience in Asia Pacific, including Australia/New Zealand, China, Malaysia, Hong Kong, India, Indonesia, The Philippines, Singapore, South Korea, Taiwan, Thailand and Japan
• Extensive knowledge of regulatory frameworks, best KOLs and sites across the region
• Vast therapeutic experience including Cardiovascular, CNS, Endocrinology, Infectious diseases, Oncology, and Respiratory
Nordion is a global health science company that provides market-leading products used for the prevention, diagnosis and treatment of disease. We are a leading provider of medical isotopes, targeted therapies and sterilization technologies that benefit the lives of millions of people in more than 60 countries around the world.
AHMC’s successful track record includes collaboration in more than 50 hospitals and projects spanning 24 countries around the world. AHMC’s hospital network consists of 32 hospital and healthcare centers, among them 13 operational facilities consisting of nearly 3,000 beds, 2,200 physicians and 5,500 employees which it has either invested in or currently manages.
ClinActis Pte Ltd is a full service CRO providing clinical trial services to the pharmaceutical, medical device, medical nutrition and biotech companies in Asia Pacific. Established in 2009, ClinActis Pte Ltd is headquartered in Singapore.
ClinActis Experience
• 45 years experience in clinical research in pharmaceutical and biotechnology companies as well as CROs
• 27 years experience in Asia Pacific, including Australia/New Zealand, China, Malaysia, Hong Kong, India, Indonesia, The Philippines, Singapore, South Korea, Taiwan, Thailand and Japan
• Extensive knowledge of regulatory frameworks, best KOLs and sites across the region
• Vast therapeutic experience including Cardiovascular, CNS, Endocrinology, Infectious diseases, Oncology, and Respiratory
Market Analysis of Clinical Research in Asia PacificClinActis Pte Ltd
ClinActis Pte Ltd is a full service CRO providing clinical trial services to the pharmaceutical, medical device, medical nutrition and biotech companies in Asia Pacific. Established in 2009, ClinActis Pte Ltd is headquartered in Singapore.
ClinActis Experience
• 33 years experience in clinical research in pharmaceutical and biotechnology companies as well as CROs
• 27 years experience in Asia Pacific, including Australia/New Zealand, China, Malaysia, Hong Kong, India, Indonesia, The Philippines, Singapore, South Korea, Taiwan, Thailand and Japan
• Extensive knowledge of regulatory frameworks, best KOLs and sites across the region
• Vast therapeutic experience including Cardiovascular, CNS, Endocrinology, Infectious diseases, Oncology, and Respiratory
Novartis is a global healthcare company based in Switzerland that provides solutions to address the evolving needs of patients worldwide. Our mission is to discover new ways to improve and extend people’s lives. Our vision is to be a trusted leader in changing the practice of medicine.
ClinActis Pte Ltd is a Clinical Research Organization specialized in Asia Pacific, providing pharmaceutical, medical device, medical nutrition and biotech companies with state of the art clinical research services with an approach fully customized to the specificities of Asia Pacific.
Our regional coverage includes Singapore, Malaysia, Thailand, The Philippines, Vietnam, Indonesia, Taiwan, Hong Kong, Korea and Australia, as well as India through our strategic alliance with an Indian CRO.
Staying Relevant in a High Volume, Commoditized, Medical Device Product Line ...marcus evans Network
Beth Krenzer, Cardinal Health - Speaker at the marcus evans Medical Device Manufacturing Summit Spring 2012, held in Las Vegas, NV, delivered his presentation entitled Staying Relevant in a High Volume, Commoditized, Medical Device Product Line in Manufacturing (Insourced and Outsourced)
Thyrocare Technologies Limited claims to be India’s most advanced totally automated laboratory having its strong presence in more than 2000 cities / towns in India and internationally.
The company was started in 1996, by Dr Velumani Arokiaswamy with a staff of 4 people, with focus on low cost Thyroid testing.
By 2014, it has become India’s most profitable diagnostic business. The company has a highly differentiated business model. It is more of a B2B company, collecting samples from hundreds of dedicated collection points, and also from allied labs. All processing is done in one highly automated lab near Mumbai.
ClinActis Pte Ltd is a full service CRO providing clinical trial services to the pharmaceutical, medical device, medical nutrition and biotech companies in Asia Pacific. Established in 2009, ClinActis Pte Ltd is headquartered in Singapore.
ClinActis Experience
• 32 years experience in clinical research in pharmaceutical and biotechnology companies as well as CROs
• 27 years experience in Asia Pacific, including Australia/New Zealand, China, Malaysia, Hong Kong, India, Indonesia, The Philippines, Singapore, South Korea, Taiwan, Thailand and Japan
• Extensive knowledge of regulatory frameworks, best KOLs and sites across the region
• Vast therapeutic experience including Cardiovascular, CNS, Endocrinology, Infectious diseases, Oncology, and Respiratory
ClinActis: Logistics of Asian Based Clinical TrialsClinActis Pte Ltd
ClinActis Overview:
ClinActis Pte Ltd is a full service CRO providing clinical trial services to the pharmaceutical, medical device, medical nutrition and biotech companies in Asia Pacific. Established in 2009, ClinActis Pte Ltd is headquartered in Singapore.
ClinActis Experience:
• 33 years experience in clinical research in pharmaceutical and biotechnology companies as well as CROs
• 27 years experience in Asia Pacific, including Australia/New Zealand, China, Malaysia, Hong Kong, India, Indonesia, The Philippines, Singapore, South Korea, Taiwan, Thailand and Japan
• Extensive knowledge of regulatory frameworks, best KOLs and sites across the region
• Vast therapeutic experience including Cardiovascular, CNS, Endocrinology, Infectious diseases, Oncology, and Respiratory
Agenda
* Introduction of Clinical Trial Country/Site Selection
* Select the Accredited Sites Outside China
* Understand the Submission Requirements in Targeted Countries (Authorized by CFDA)
* Challenges and Consideration to Conduct PK Bridging Study Outside China
* Estimation of the Patient Cost in Targeted Countries
* Conclusion on the Country/Site Selection
iHT² Health IT Summit New York - Mark MacNaughton, SVP & CIO, Medial Segment at Cardinal Health - Keynote Presentation “Information as an Asset - Moving From the T Side of IT to the I”
ClinActis Pte Ltd is a full service CRO providing clinical trial services to the pharmaceutical, medical device, medical nutrition and biotech companies in Asia Pacific. Established in 2009, ClinActis Pte Ltd is headquartered in Singapore.
ClinActis Experience
• 33 years experience in clinical research in pharmaceutical and biotechnology companies as well as CROs
• 27 years experience in Asia Pacific, including Australia/New Zealand, China, Malaysia, Hong Kong, India, Indonesia, The Philippines, Singapore, South Korea, Taiwan, Thailand and Japan
• Extensive knowledge of regulatory frameworks, best KOLs and sites across the region
• Vast therapeutic experience including Cardiovascular, CNS, Endocrinology, Infectious diseases, Oncology, and Respiratory
ClinActis Pte Ltd is a Clinical Research Organization specialized in Asia Pacific, providing pharmaceutical, medical device, medical nutrition and biotech companies with state of the art clinical research services with an approach fully customized to the specificities of Asia Pacific.
Our regional coverage includes Singapore, Malaysia, Thailand, The Philippines, Vietnam, Indonesia, Taiwan, Hong Kong, Korea and Australia, as well as India through our strategic alliance with an Indian CRO.
Novartis is a global healthcare company based in Switzerland that provides solutions to address the evolving needs of patients worldwide. Our mission is to discover new ways to improve and extend people’s lives. Our vision is to be a trusted leader in changing the practice of medicine.
ClinActis Pte Ltd is a Clinical Research Organization specialized in Asia Pacific, providing pharmaceutical, medical device, medical nutrition and biotech companies with state of the art clinical research services with an approach fully customized to the specificities of Asia Pacific.
Our regional coverage includes Singapore, Malaysia, Thailand, The Philippines, Vietnam, Indonesia, Taiwan, Hong Kong, Korea and Australia, as well as India through our strategic alliance with an Indian CRO.
Staying Relevant in a High Volume, Commoditized, Medical Device Product Line ...marcus evans Network
Beth Krenzer, Cardinal Health - Speaker at the marcus evans Medical Device Manufacturing Summit Spring 2012, held in Las Vegas, NV, delivered his presentation entitled Staying Relevant in a High Volume, Commoditized, Medical Device Product Line in Manufacturing (Insourced and Outsourced)
Thyrocare Technologies Limited claims to be India’s most advanced totally automated laboratory having its strong presence in more than 2000 cities / towns in India and internationally.
The company was started in 1996, by Dr Velumani Arokiaswamy with a staff of 4 people, with focus on low cost Thyroid testing.
By 2014, it has become India’s most profitable diagnostic business. The company has a highly differentiated business model. It is more of a B2B company, collecting samples from hundreds of dedicated collection points, and also from allied labs. All processing is done in one highly automated lab near Mumbai.
ClinActis Pte Ltd is a full service CRO providing clinical trial services to the pharmaceutical, medical device, medical nutrition and biotech companies in Asia Pacific. Established in 2009, ClinActis Pte Ltd is headquartered in Singapore.
ClinActis Experience
• 32 years experience in clinical research in pharmaceutical and biotechnology companies as well as CROs
• 27 years experience in Asia Pacific, including Australia/New Zealand, China, Malaysia, Hong Kong, India, Indonesia, The Philippines, Singapore, South Korea, Taiwan, Thailand and Japan
• Extensive knowledge of regulatory frameworks, best KOLs and sites across the region
• Vast therapeutic experience including Cardiovascular, CNS, Endocrinology, Infectious diseases, Oncology, and Respiratory
ClinActis: Logistics of Asian Based Clinical TrialsClinActis Pte Ltd
ClinActis Overview:
ClinActis Pte Ltd is a full service CRO providing clinical trial services to the pharmaceutical, medical device, medical nutrition and biotech companies in Asia Pacific. Established in 2009, ClinActis Pte Ltd is headquartered in Singapore.
ClinActis Experience:
• 33 years experience in clinical research in pharmaceutical and biotechnology companies as well as CROs
• 27 years experience in Asia Pacific, including Australia/New Zealand, China, Malaysia, Hong Kong, India, Indonesia, The Philippines, Singapore, South Korea, Taiwan, Thailand and Japan
• Extensive knowledge of regulatory frameworks, best KOLs and sites across the region
• Vast therapeutic experience including Cardiovascular, CNS, Endocrinology, Infectious diseases, Oncology, and Respiratory
Agenda
* Introduction of Clinical Trial Country/Site Selection
* Select the Accredited Sites Outside China
* Understand the Submission Requirements in Targeted Countries (Authorized by CFDA)
* Challenges and Consideration to Conduct PK Bridging Study Outside China
* Estimation of the Patient Cost in Targeted Countries
* Conclusion on the Country/Site Selection
iHT² Health IT Summit New York - Mark MacNaughton, SVP & CIO, Medial Segment at Cardinal Health - Keynote Presentation “Information as an Asset - Moving From the T Side of IT to the I”
ClinActis Pte Ltd is a full service CRO providing clinical trial services to the pharmaceutical, medical device, medical nutrition and biotech companies in Asia Pacific. Established in 2009, ClinActis Pte Ltd is headquartered in Singapore.
ClinActis Experience
• 33 years experience in clinical research in pharmaceutical and biotechnology companies as well as CROs
• 27 years experience in Asia Pacific, including Australia/New Zealand, China, Malaysia, Hong Kong, India, Indonesia, The Philippines, Singapore, South Korea, Taiwan, Thailand and Japan
• Extensive knowledge of regulatory frameworks, best KOLs and sites across the region
• Vast therapeutic experience including Cardiovascular, CNS, Endocrinology, Infectious diseases, Oncology, and Respiratory
ClinActis Pte Ltd is a Clinical Research Organization specialized in Asia Pacific, providing pharmaceutical, medical device, medical nutrition and biotech companies with state of the art clinical research services with an approach fully customized to the specificities of Asia Pacific.
Our regional coverage includes Singapore, Malaysia, Thailand, The Philippines, Vietnam, Indonesia, Taiwan, Hong Kong, Korea and Australia, as well as India through our strategic alliance with an Indian CRO.
Strategi bisnis untuk pengembangan produk kemasan terhadap kepuasan pelanggan, karena kemasan dalam suatu produk itu sangat harus diperhatikan betul oleh pelaku bisnis, karena yang pertama dilihat oleh konsumen yaitu kemasannya baru melihat produk nya jadi kemasan suatu produk itu sangat harus diperhatikan
Vanjaar se Wêreld Kankerdag wat op Saterdag 4 Februarie plaasvind, sit die tema van 2016 se Wêreld Kankerdag ‘Ons kan, Ek kan’,- veldtog voort. Die tema van die veldtog aksentueer hoe elkeen – gesamentlik of indiwidueel – kan saamspan om te help om die globale las van kanker te verlig en om die risiko’s van kanker te verminder. “Inspireer aksie. Neem aksie” is die boodskap wat KANSA , in 2017 gaan beklemtoon.
Lees meer: http://www.cansa.org.za/wereld-kankerdag-4-februarie-2017-inspireer-aksie-neem-aksie/
Through practical case studies and industry specific analysis sessions, Medical Device UDIs & Traceability Forum Europe 2015 is geared around strengthening your regulatory infrastructure, maintaining productivity and ensuring ROI from your UDI projects.
View the full agenda here: bit.ly/MedicalDeviceUDI2015Agenda
Alternatively, email enquire@iqpc.co.uk or call +44 (0)207 036 1300 for a copy.
Cell & Gene Therapy post-approval solutions to reduce scientific, regulatory and commercial risks, and accelerate development wherever you are in your product's development.
Oats Processing Plant Project Report PPT | Plant Cost 2023: Machinery, Raw Ma...IMARC Group
The report provides a complete roadmap for setting up an Oats Processing Plant. It covers a comprehensive market overview to micro-level information such as unit operations involved, raw material requirements, utility requirements, infrastructure requirements, machinery and technology requirements, manpower requirements, packaging requirements, transportation requirements, etc.
New Directions in Targeted Therapeutic Approaches for Older Adults With Mantl...i3 Health
i3 Health is pleased to make the speaker slides from this activity available for use as a non-accredited self-study or teaching resource.
This slide deck presented by Dr. Kami Maddocks, Professor-Clinical in the Division of Hematology and
Associate Division Director for Ambulatory Operations
The Ohio State University Comprehensive Cancer Center, will provide insight into new directions in targeted therapeutic approaches for older adults with mantle cell lymphoma.
STATEMENT OF NEED
Mantle cell lymphoma (MCL) is a rare, aggressive B-cell non-Hodgkin lymphoma (NHL) accounting for 5% to 7% of all lymphomas. Its prognosis ranges from indolent disease that does not require treatment for years to very aggressive disease, which is associated with poor survival (Silkenstedt et al, 2021). Typically, MCL is diagnosed at advanced stage and in older patients who cannot tolerate intensive therapy (NCCN, 2022). Although recent advances have slightly increased remission rates, recurrence and relapse remain very common, leading to a median overall survival between 3 and 6 years (LLS, 2021). Though there are several effective options, progress is still needed towards establishing an accepted frontline approach for MCL (Castellino et al, 2022). Treatment selection and management of MCL are complicated by the heterogeneity of prognosis, advanced age and comorbidities of patients, and lack of an established standard approach for treatment, making it vital that clinicians be familiar with the latest research and advances in this area. In this activity chaired by Michael Wang, MD, Professor in the Department of Lymphoma & Myeloma at MD Anderson Cancer Center, expert faculty will discuss prognostic factors informing treatment, the promising results of recent trials in new therapeutic approaches, and the implications of treatment resistance in therapeutic selection for MCL.
Target Audience
Hematology/oncology fellows, attending faculty, and other health care professionals involved in the treatment of patients with mantle cell lymphoma (MCL).
Learning Objectives
1.) Identify clinical and biological prognostic factors that can guide treatment decision making for older adults with MCL
2.) Evaluate emerging data on targeted therapeutic approaches for treatment-naive and relapsed/refractory MCL and their applicability to older adults
3.) Assess mechanisms of resistance to targeted therapies for MCL and their implications for treatment selection
micro teaching on communication m.sc nursing.pdfAnurag Sharma
Microteaching is a unique model of practice teaching. It is a viable instrument for the. desired change in the teaching behavior or the behavior potential which, in specified types of real. classroom situations, tends to facilitate the achievement of specified types of objectives.
The prostate is an exocrine gland of the male mammalian reproductive system
It is a walnut-sized gland that forms part of the male reproductive system and is located in front of the rectum and just below the urinary bladder
Function is to store and secrete a clear, slightly alkaline fluid that constitutes 10-30% of the volume of the seminal fluid that along with the spermatozoa, constitutes semen
A healthy human prostate measures (4cm-vertical, by 3cm-horizontal, 2cm ant-post ).
It surrounds the urethra just below the urinary bladder. It has anterior, median, posterior and two lateral lobes
It’s work is regulated by androgens which are responsible for male sex characteristics
Generalised disease of the prostate due to hormonal derangement which leads to non malignant enlargement of the gland (increase in the number of epithelial cells and stromal tissue)to cause compression of the urethra leading to symptoms (LUTS
Pulmonary Thromboembolism - etilogy, types, medical- Surgical and nursing man...VarunMahajani
Disruption of blood supply to lung alveoli due to blockage of one or more pulmonary blood vessels is called as Pulmonary thromboembolism. In this presentation we will discuss its causes, types and its management in depth.
Explore natural remedies for syphilis treatment in Singapore. Discover alternative therapies, herbal remedies, and lifestyle changes that may complement conventional treatments. Learn about holistic approaches to managing syphilis symptoms and supporting overall health.
NVBDCP.pptx Nation vector borne disease control programSapna Thakur
NVBDCP was launched in 2003-2004 . Vector-Borne Disease: Disease that results from an infection transmitted to humans and other animals by blood-feeding arthropods, such as mosquitoes, ticks, and fleas. Examples of vector-borne diseases include Dengue fever, West Nile Virus, Lyme disease, and malaria.
Knee anatomy and clinical tests 2024.pdfvimalpl1234
This includes all relevant anatomy and clinical tests compiled from standard textbooks, Campbell,netter etc..It is comprehensive and best suited for orthopaedicians and orthopaedic residents.
ARTIFICIAL INTELLIGENCE IN HEALTHCARE.pdfAnujkumaranit
Artificial intelligence (AI) refers to the simulation of human intelligence processes by machines, especially computer systems. It encompasses tasks such as learning, reasoning, problem-solving, perception, and language understanding. AI technologies are revolutionizing various fields, from healthcare to finance, by enabling machines to perform tasks that typically require human intelligence.
These lecture slides, by Dr Sidra Arshad, offer a quick overview of physiological basis of a normal electrocardiogram.
Learning objectives:
1. Define an electrocardiogram (ECG) and electrocardiography
2. Describe how dipoles generated by the heart produce the waveforms of the ECG
3. Describe the components of a normal electrocardiogram of a typical bipolar leads (limb II)
4. Differentiate between intervals and segments
5. Enlist some common indications for obtaining an ECG
Study Resources:
1. Chapter 11, Guyton and Hall Textbook of Medical Physiology, 14th edition
2. Chapter 9, Human Physiology - From Cells to Systems, Lauralee Sherwood, 9th edition
3. Chapter 29, Ganong’s Review of Medical Physiology, 26th edition
4. Electrocardiogram, StatPearls - https://www.ncbi.nlm.nih.gov/books/NBK549803/
5. ECG in Medical Practice by ABM Abdullah, 4th edition
6. ECG Basics, http://www.nataliescasebook.com/tag/e-c-g-basics
Prix Galien International 2024 Forum ProgramLevi Shapiro
June 20, 2024, Prix Galien International and Jerusalem Ethics Forum in ROME. Detailed agenda including panels:
- ADVANCES IN CARDIOLOGY: A NEW PARADIGM IS COMING
- WOMEN’S HEALTH: FERTILITY PRESERVATION
- WHAT’S NEW IN THE TREATMENT OF INFECTIOUS,
ONCOLOGICAL AND INFLAMMATORY SKIN DISEASES?
- ARTIFICIAL INTELLIGENCE AND ETHICS
- GENE THERAPY
- BEYOND BORDERS: GLOBAL INITIATIVES FOR DEMOCRATIZING LIFE SCIENCE TECHNOLOGIES AND PROMOTING ACCESS TO HEALTHCARE
- ETHICAL CHALLENGES IN LIFE SCIENCES
- Prix Galien International Awards Ceremony
2. Caution on Forward Looking Statements
This presentation contains forward-looking statements, within the meaning of applicable securities laws, including under
applicable Canadian securities laws and the “safe harbor” provisions of the United States Private Securities Litigation Reform Act
of 1995. These statements can be identified by expressions of belief, expectation or intention, as well as those statements that
are not historical fact. The words “may”, “will”, “could”, “should”, “would”, “outlook”, “believe”, “plan”, “anticipate”, “estimate”,
“expect” and similar words and expressions are also intended to identify forward-looking statements. Forward-looking statements
are necessarily based on estimates and assumptions made by us in light of our experience and our perception of historical
trends, current conditions and expected future developments, as well as other factors that we believe are appropriate in the
circumstances, but which are inherently subject to significant business, political, economic and competitive uncertainties and
contingencies. Known and unknown factors could cause actual results to differ materially from those projected in the forwardlooking statements. Accordingly, this presentation is subject to the disclaimer and qualified by the assumptions, qualifications and
risk factors referred to in our 2013 Annual Information Form (AIF).
We caution readers not to place undue reliance on the Company’s forward-looking statements, as a number of factors could
cause our actual results, performance or achievements to differ materially from any forward-looking statements. We do not
assume any obligation to update or revise any forward-looking statements, whether written or oral, that may be made from time
to time by us or on our behalf, except as required by applicable law.
2
3. About Nordion
Nordion is a health science company that
provides market-leading products used for
the prevention, diagnosis and treatment of
disease.
Delivering quality products to our global
customers for more than 60 years, our product
portfolio includes:
• Sterilization Technologies
• Medical Isotopes
3
4. A Global Company
F2013 REVENUES BY REGION - $232.8M*
64%
UNITED STATES
Finance
23%
5%
CANADA
APPROXIMATELY
400 EMPLOYEES
AROUND
30 PRODUCTS
ROW
8%
EUROPE
SUPPLY OVER
500 CUSTOMERS
ACROSS MORE THAN
40 COUNTRIES
4
*Revenues and regional breakdown include Targeted Therapies business, which was divested in July 2013 to BTG plc.
5. 2013 Financial Highlights
Revenue Trend (US$ Millions)
Sterilization Technologies
Medical Isotopes
Targeted Therapies*
300
250
42.6
48.5
36.3
101
100.3
108.7
95.4
96.1
2011
2012
2013
200
150
122.8
100
50
0
* In July 2013, Nordion divested its Targeted Therapies business to BTG plc
5
6. 2013 Financial Highlights
Segment Earnings Trend (US$ Millions)
Sterilization Technologies
Medical Isotopes
Targeted Therapies*
120
100
12.7
80
60
14.1
38.3
3
29.4
25.9
40
20
0
46.1
39
35.3
2011
2012
2013
Excludes corporate segmented loss
* In July 2013, Nordion divested its Targeted Therapies business to BTG plc
6
7. Q4 2013 Results
Sterilization Technologies
Targeted Therapies**
Medical Isotopes
Segmented Revenue
80
70
(US$ millions)
35
30
12.0
60
50
2.8
11.3
30.3
20
28.4
30
15
10
32.3
23
10
0
(US$ millions)
25
40
20
Segmented Earnings*
2012
Q4
2013
* Excludes corporate segmented loss
** In July 2013, Nordion divested its Targeted Therapies business to BTG plc
7.8
16.7
5
0
7.6
2012
Q4
2013
7
9. Leading Products in Global Markets
STERILIZATION
TECHNOLOGIES
MEDICAL
ISOTOPES
Maintain Sterilization business;
selectively invest in growth:
• Geographic expansion
• New applications
Optimize Medical Isotopes business
• Secure long-term supply
• Maintain customer relationships
POTENTIAL >
Approximately 40% of single-use medical
products worldwide are sterilized using
gamma sterilization technologies
Over 10,000 hospitals worldwide use
radioisotopes in medical procedures with
about 90% being for diagnosis.
ADVANTAGE >
• Global leader in cobalt-60
• Significant barriers to entry
• Solid cash flow and gross margins
• Recurring revenue base
• A global provider in processing,
packaging, & delivery
• Extensive regulatory expertise and
logistics & distribution network
PRIORITY >
9
10. Specialty Isotopes: Sterilization Technologies
•
Gamma sterilization is focused on
the prevention of disease
•
Co-60 is used to sterilize medical devices,
instruments and supplies and food
•
Customers of Co-60 include
contract sterilization service providers
and medical device and product manufacturers
•
The Nordion Gamma Centre of Excellence is a
world class applied research and specialty gamma
processing facility to promote and expand the use
of gamma globally
•
Nordion manufactures Co-60 irradiation sources,
and designs, constructs and maintains commercial
gamma sterilization systems
10
11. Sterilization Market Segmentation
MARKET MIX
PRODUCTS
DRIVERS
• Syringes
MEDICAL & SURGICAL
10%
BIO-ACTIVE DEVICES
+ Min invasive surgery
• Drapes, gowns
+ Smaller devices
• Sutures, gloves
80%
80%
+ Aging population
• Catheters
+ Material
• Stents
• Patches
• Tissue
• Regen medicine
• Fruits & vegetables
10%
10%
• Spices
• Meat and poultry
FOOD SAFETY
• Ready To Eat (RTE)
+ Aging population
+ Enhance devices
+ Leverage drugs
+ Stem cell research
+ FDA labeling
+ USDA FEA
+ Food safety concerns
11
12. Specialty Isotopes: Medical Isotopes
•
Medical isotopes are used to prevent, diagnose and treat disease
•
Main isotope supply sources
are nuclear reactors and cyclotrons
•
Primary product is Mo-99, which decays for use in Technetium-99
(Tc-99m) generators, used in imaging to diagnose heart disease and
cancers
•
Other Key Reactor Isotopes:
–
Iodine-131 (I-131), used to treat hyperthyroidism, thyroid cancer and non-Hodgkin’s lymphoma;
–
Iodine-125 (I-125), used to treat prostate cancer;
–
•
Xenon-133 (Xe-133), used in lung scans;
–
Yttrium-90 (Y-90), used to treat liver cancer.
Key Cyclotron Isotopes:
–
Iodine-123 (I-123), used to diagnose thyroid disease;
–
Strontium-82 (Sr-82), used to manufacture rubidium-82 generators, which are used in imaging
to diagnose heart disease
–
Thallium-201 (Tl-201), used to diagnose and assess risk of coronary artery heart disease;
–
Palladium-103 (Pd-103), used to treat prostate cancer;
–
Indium-111 (In-111) and Gallium-67 (Ga-67) (both used to diagnose infection and cancer) at our
Vancouver facilities
12
13. Medical Isotopes (Mo-99) Supply Chain
NUCLEAR
REACTORS
RADIOPHARMACEUTICAL
MANUFACTURERS
RADIOPHARMACIES
AND HOSPITALS
PHYSICIANS
AND PATIENTS
Irradiation of
HEU targets to
produce crude
isotopes
•
•
MEDICAL ISOTOPE
PROCESSORS
Purification of
Mo-99 and
distribution to global
radiopharmaceutical
manufacturers
Tc-99m
Generator
manufacturing
and distribution to
radiopharmacies
Unit dose
compounding and
distribution to
hospital/departments
Critical physiological
diagnosis enabling
informed therapeutic
decisions
Established, reliable facilities providing high-quality isotopes to global customers
Specialty skills in operations, regulatory affairs and global logistics
13
14. Nordion Environmental, Health,
and Safety (EH&S) Program
• Creating a workplace that enriches
the health and well-being of Nordion
employees
• Demonstrating Environmental, Health,
and Safety (EH&S) regulatory excellence
• Improving EH&S performance –
continually
• Managing EH&S with excellence
Recipient of Canada’s Safest
Employers - Gold level award
October, 2013
14
15. Nordion Environmental, Health,
and Safety (EH&S) Program
•
Implementing measures in the design and operation of all of
our facilities to keep radiation dose received by workers and
the public ALARA (as low as reasonably achievable)
•
Implementing an ISO 14001-based environmental
management (EMS) system at our Ottawa site
•
Establishing EH&S objectives and targets annually
to continually improve our performance
•
Maintaining - and building on - a comprehensive training
program for employees and contractors
•
Engraining EH&S excellence into the Nordion culture
•
Investing in a world class approach to EH&S
ISO 14001: 2004 certified
Recipient of the Government of Canada 2007 ENERGY STAR ® Market Transformation Award
Practitioner of LeanSigma, a methodology used to continually improve processes
Recipient of an unprecedented ten-year license renewal from the Canadian Nuclear Safety Commission (CNSC)
15
16. In the Community
Ride the Rideau
Sponsor of Ride the Rideau since its inauguration in 2010, Nordion has helped to raise
over $6.4 million for cancer research at The Ottawa Hospital Research Institute.
Other Programs:
• Employee Giving Program - Nordion
makes donations to not-for-profit
organizations nominated by employees
• Proud sponsor of the Gala for Research,
an annual black-tie event to support
the Ottawa Hospital Research Institute,
the research arm of The Ottawa Hospital
16
17. Business Outlook
The talented, dedicated and
resilient people that make up
Nordion share a single
purpose:
• Maintain a global leadership position
in our key markets
• Build value for shareholders through
the execution of our strategic
priorities
• Be a trusted, world-class provider of
healthcare products to our customers
17
18. Find out more at
www.nordion.com
Follow us at
http://twitter.com/NordionInc
www.nordion.com